OneSource Specialty Pharma (BOM:544292) Total Equity: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544292 OneSource Specialty Pharma Ltd BOM:544292
8 GF Score
Price ₹1,481.35
! 3 Warning Signs
View Full Analysis

What is OneSource Specialty Pharma Total Equity?

OneSource Specialty Pharma BOM:544292 -2.04% 8 Total Equity is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:544292 with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

OneSource Specialty Pharma's total equity for the quarter that ended in Jun. 2026 was ₹0 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

OneSource Specialty Pharma Total Equity Historical Data

* Premium members only.

The historical data trend for OneSource Specialty Pharma's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OneSource Specialty Pharma Total Equity Chart

OneSource Specialty Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
Total Equity
7,854.53 3,957.13 58,805.79 58,312.89

OneSource Specialty Pharma Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 59,044.72 0.00 58,312.89 0.00
BOM:544292
8GF Score
OneSource Specialty Pharma Ltd BOM:544292
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OneSource Specialty Pharma Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

OneSource Specialty Pharma's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=82100.14-23787.25
=58,313

OneSource Specialty Pharma's Total Equity for the quarter that ended in Jun. 2026 is calculated as

Total Equity=Total Assets(Q: Jun. 2026 )-Total Liabilities(Q: Jun. 2026 )
=N/A-N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of ₹0 Mil mean?
OneSource Specialty Pharma (BOM:544292) has a Total Equity of ₹0 Mil as of Jun. 2026. The total amount of equity as record on a company's balance sheet. View historical data for OneSource Specialty Pharma and its competitors.
Is OneSource Specialty Pharma's Total Equity too high?
OneSource Specialty Pharma's current Total Equity is ₹0 Mil. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Total Equity compare to VRTX and REGN?
OneSource Specialty Pharma's Total Equity of ₹0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for OneSource Specialty Pharma and its competitors. OneSource Specialty Pharma's current Total Equity is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (BOM:544292) has a current Total Equity of ₹0 Mil. The current Total Equity is ₹0 Mil. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For OneSource Specialty Pharma (BOM:544292), the current Total Equity is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OneSource Specialty Pharma Business Description

Other Exchanges ONESOURCE:India
Address Bannerghatta Road, Star 1, Opp IIM Bangalore, Bilekahalli, Bangalore, KA, IND, 560076
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score

Get the complete analysis for BOM:544292

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,481.35
Price